Advanced search
Publication Cover
Expert Review of Clinical Pharmacology Volume 5, 2012 - Issue 6
Submit an article Journal homepage
114
Views
26
CrossRef citations to date
0
Altmetric
Drug Profile

Pharmacologic and clinical profile of dexamethasone intravitreal implant

Michael R Robinson Allergan, Inc., 2525 Dupont Drive, Irvine, CA, 92612-1531, USA. [email protected]
&
Scott M Whitcup Allergan, Inc., 2525 Dupont Drive, Irvine, CA, 92612-1531, USA
Pages 629-647 | Published online: 10 Jan 2014

References

  • Green WR, Chan CC, Hutchins GM, Terry JM. Central retinal vein occlusion: a prospective histopathologic study of 29 eyes in 28 cases. Trans. Am. Ophthalmol. Soc. 79, 371–422 (1981).
  • Durrani OM, Meads CA, Murray PI. Uveitis: a potentially blinding disease. Ophthalmologica 218(4), 223–236 (2004).
  • Hardman JG, Limbird LE, Molinoff PB et al. Goodman and Gilman’s Pharmacological Basis of Therapeutics. (9th Edition). Pergamon Press, NY, USA (1996).
  • Campochiaro PA, Hafiz G, Shah SM et al. Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator. Mol. Ther. 16(4), 791–799 (2008).
  • Funatsu H, Noma H, Mimura T, Eguchi S, Hori S. Association of vitreous inflammatory factors with diabetic macular edema. Ophthalmology 116(1), 73–79 (2009).
  • Funk M, Kriechbaum K, Prager F et al. Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumab. Invest. Ophthalmol. Vis. Sci. 50(3), 1025–1032 (2009).
  • Pe’er J, Folberg R, Itin A, Gnessin H, Hemo I, Keshet E. Vascular endothelial growth factor upregulation in human central retinal vein occlusion. Ophthalmology 105(3), 412–416 (1998).
  • Antonetti DA, Barber AJ, Khin S, Lieth E, Tarbell JM, Gardner TW. Vascular permeability in experimental diabetes is associated with reduced endothelial occludin content: vascular endothelial growth factor decreases occludin in retinal endothelial cells. Penn State Retina Research Group. Diabetes 47(12), 1953–1959 (1998).
  • Antcliff RJ, Marshall J. The pathogenesis of edema in diabetic maculopathy. Semin. Ophthalmol. 14(4), 223–232 (1999).
  • Bhagat N, Grigorian RA, Tutela A, Zarbin MA. Diabetic macular edema: pathogenesis and treatment. Surv. Ophthalmol. 54(1), 1–32 (2009).
  • Renfro L, Snow JS. Ocular effects of topical and systemic steroids. Dermatol. Clin. 10(3), 505–512 (1992).
  • Weijtens O, Schoemaker RC, Romijn FP, Cohen AF, Lentjes EG, van Meurs JC. Intraocular penetration and systemic absorption after topical application of dexamethasone disodium phosphate. Ophthalmology 109(10), 1887–1891 (2002).
  • Weijtens O, Schoemaker RC, Lentjes EG, Romijn FP, Cohen AF, van Meurs JC. Dexamethasone concentration in the subretinal fluid after a subconjunctival injection, a peribulbar injection, or an oral dose. Ophthalmology 107(10), 1932–1938 (2000).
  • Guly CM, Forrester JV. Investigation and management of uveitis. Br. Med. J. 341, c4976 (2010).
  • Weijtens O, Feron EJ, Schoemaker RC et al. High concentration of dexamethasone in aqueous and vitreous after subconjunctival injection. Am. J. Ophthalmol. 128(2), 192–197 (1999).
  • Ghate D, Edelhauser HF. Ocular drug delivery. Expert Opin. Drug Deliv. 3(2), 275–287 (2006).
  • Jager RD, Aiello LP, Patel SC, Cunningham ET Jr. Risks of intravitreous injection: a comprehensive review. Retina 24(5), 676–698 (2004).
  • Lee SS, Hughes P, Ross AD, Robinson MR. Biodegradable implants for sustained drug release in the eye. Pharm. Res. 27(10), 2043–2053 (2010).
  • Hosoya K, Tachikawa M. Inner blood–retinal barrier transporters: role of retinal drug delivery. Pharm. Res. 26(9), 2055–2065 (2009).
  • Nguyen QD, Callanan D, Dugel P, Godfrey DG, Goldstein DA, Wilensky JT. Treating chronic noninfectious posterior segment uveitis: the impact of cumulative damage. Proceedings of an expert panel roundtable discussion. Retina (Suppl.), 1–16 (2006).
  • Weijtens O, Schoemaker RC, Cohen AF et al. Dexamethasone concentration in vitreous and serum after oral administration. Am. J. Ophthalmol. 125(5), 673–679 (1998).
  • Kwak HW, D’Amico DJ. Evaluation of the retinal toxicity and pharmacokinetics of dexamethasone after intravitreal injection. Arch. Ophthalmol. 110(2), 259–266 (1992).
  • Takeda AL, Colquitt J, Clegg AJ, Jones J. Pegaptanib and ranibizumab for neovascular age-related macular degeneration: a systematic review. Br. J. Ophthalmol. 91(9), 1177–1182 (2007).
  • Campochiaro PA, Heier JS, Feiner L et al.; BRAVO Investigators. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a Phase III study. Ophthalmology 117(6), 1102–1112.e1 (2010).
  • Brown DM, Campochiaro PA, Singh RP et al.; CRUISE Investigators. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a Phase III study. Ophthalmology 117(6), 1124–1133.e1 (2010).
  • Stewart MW, Grippon S, Kirkpatrick P. Aflibercept. Nat. Rev. Drug Discov. 11(4), 269–270 (2012).
  • Lowder C, Belfort R Jr, Lightman S et al.; Ozurdex HURON Study Group. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch. Ophthalmol. 129(5), 545–553 (2011).
  • Haller JA, Bandello F, Belfort R Jr et al.; Ozurdex GENEVA Study Group. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion: twelve-month study results. Ophthalmology 118(12), 2453–2460 (2011).
  • Ip MS, Scott IU, VanVeldhuisen PC et al.; SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch. Ophthalmol. 127(9), 1101–1114 (2009).
  • Scott IU, Ip MS, VanVeldhuisen PC et al.; SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch. Ophthalmol. 127(9), 1115–1128 (2009).
  • Jaffe GJ, Martin D, Callanan D, Pearson PA, Levy B, Comstock T; Fluocinolone Acetonide Uveitis Study Group. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology 113(6), 1020–1027 (2006).
  • Callanan DG, Jaffe GJ, Martin DF, Pearson PA, Comstock TL. Treatment of posterior uveitis with a fluocinolone acetonide implant: three-year clinical trial results. Arch. Ophthalmol. 126(9), 1191–1201 (2008).
  • Ohr M, Kaiser PK. Intravitreal aflibercept injection for neovascular (wet) age-related macular degeneration. Expert Opin. Pharmacother. 13(4), 585–591 (2012).
  • Micieli JA, Micieli A, Smith AF. Identifying systemic safety signals following intravitreal bevacizumab: systematic review of the literature and the Canadian Adverse Drug Reaction Database. Can. J. Ophthalmol. 45(3), 231–238 (2010).
  • Lock JH, Fong KC. Retinal laser photocoagulation. Med. J. Malaysia 65(1), 88–94; quiz 95 (2010).
  • Mason JO 3rd, Colagross CT, Vail R. Diabetic vitrectomy: risks, prognosis, future trends. Curr. Opin. Ophthalmol. 17(3), 281–285 (2006).
  • Sivaprasad S, Elagouz M, McHugh D, Shona O, Dorin G. Micropulsed diode laser therapy: evolution and clinical applications. Surv. Ophthalmol. 55(6), 516–530 (2010).
  • Shultz RW, Bakri SJ. Treatment for submacular hemorrhage associated with neovascular age-related macular degeneration. Semin. Ophthalmol. 26(6), 361–371 (2011).
  • Bonfioli AA, Damico FM, Curi AL, Orefice F. Intermediate uveitis. Semin. Ophthalmol. 20(3), 147–154 (2005).
  • Leopold IH. Nonsteroidal and steroidal anti-inflammatory agents. In: Surgical Pharmacology of the Eye. Sears M, Tarkkanen A (Eds.). Raven Press, NY, USA, 83–133 (1985).
  • Smithen LM, Ober MD, Maranan L, Spaide RF. Intravitreal triamcinolone acetonide and intraocular pressure. Am. J. Ophthalmol. 138(5), 740–743 (2004).
  • Lorenzo Carrero J, González Barcia M, Pérez Flores I. Sterile endophthalmitis after benzyl alcohol filtered triamcinolone acetonide injection. Arch. Ophthalmol. 126(1), 142–143 (2008).
  • Maia M, Farah ME, Belfort RN et al. Effects of intravitreal triamcinolone acetonide injection with and without preservative. Br. J. Ophthalmol. 91(9), 1122–1124 (20s).
  • Beck RW, Edwards AR, Aiello LP et al.; Diabetic Retinopathy Clinical Research Network (DRCR.net). Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch. Ophthalmol. 127(3), 245–251 (2009).
  • Roth D, Lee SS, Flynn JHW, Moshfeghi DM. Inflammatory reactions after intravitreal triamcinolone acetonide: possible mechanisms and therapeutic options. Exp. Rev. Opthalmol. 5, 273–276 (2010).
  • Krah JL, Krimmel D, Dodwell D. Sterile enpophthalmitis secondary to intravitreal Triesence (triamcinolone acetonide). IOVS 50, 3565 (2009).
  • Bhavsar AR, Ip MS, Glassman AR; DRCRnet and the SCORE Study Groups. The risk of endophthalmitis following intravitreal triamcinolone injection in the DRCRnet and SCORE clinical trials. Am. J. Ophthalmol. 144(3), 454–456 (2007).
  • Goldstein DA, Godfrey DG, Hall A et al. Intraocular pressure in patients with uveitis treated with fluocinolone acetonide implants. Arch. Ophthalmol. 125(11), 1478–1485 (2007).
  • Morley MG, Duker JS, Ashton P, Robinson MR. Replacing ganciclovir implants. Ophthalmology 102(3), 388–392 (1995).
  • Campochiaro PA, Brown DM, Pearson A et al.; FAME Study Group. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology doi:10.1111/j.1471-4159.2012.07842 (2012) (Epub ahead of Print).
  • Haller JA, Bandello F, Belfort R Jr et al.; OZURDEX GENEVA Study Group. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 117(6), 1134–1146.e3 (2010).
  • Sneader W. Drug Discovery: A history. John Wiley and Sons, Ltd., West Sussex, UK, 208 (2005).
  • Maxwell DP Jr, Brent BD, Diamond JG, Wu L. Effect of intravitreal dexamethasone on ocular histopathology in a rabbit model of endophthalmitis. Ophthalmology 98(9), 1370–1375 (1991).
  • Nabih M, Peyman GA, Tawakol ME, Naguib K. Toxicity of high-dose intravitreal dexamethasone. Int. Ophthalmol. 15(4), 233–235 (1991).
  • Antonetti DA, Wolpert EB, DeMaio L, Harhaj NS, Scaduto RC Jr. Hydrocortisone decreases retinal endothelial cell water and solute flux coincident with increased content and decreased phosphorylation of occludin. J. Neurochem. 80(4), 667–677 (2002).
  • Edelman JL, Lutz D, Castro MR. Corticosteroids inhibit VEGF-induced vascular leakage in a rabbit model of blood–retinal and blood–aqueous barrier breakdown. Exp. Eye Res. 80(2), 249–258 (2005).
  • Nauck M, Karakiulakis G, Perruchoud AP, Papakonstantinou E, Roth M. Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. Eur. J. Pharmacol. 341(2–3), 309–315 (1998).
  • Mogensen TH, Berg RS, Paludan SR, Østergaard L. Mechanisms of dexamethasone-mediated inhibition of Toll-like receptor signaling induced by Neisseria meningitidis and Streptococcus pneumoniae. Infect. Immun. 76(1), 189–197 (2008).
  • Lee SS, Hughes P, Ross AD, Robinson MR. Advances in biodegradable ocular drug delivery systems. In: Drug Product Development for the Back of the Eye. Kompella UB, Edelhauser HF (Eds). AAPS Press, VA, USA 185–230 (2011).
  • Avgoustakis K. Polylactic-co-glycolic acid (PLGA). In: Encyclopedia of Biomaterials and Biomedical Engineering. Wnek GE, Bowlin GL (Eds). Informa Healthcare Inc., NY, USA 2259–2269 (2008).
  • Kulkarni RK, Pani KC, Neuman C, Leonard F. Polylactic acid for surgical implants. Arch. Surg. 93(5), 839–843 (1966).
  • Haller JA, Dugel P, Weinberg DV, Chou C, Whitcup SM. Evaluation of the safety and performance of an applicator for a novel intravitreal dexamethasone drug delivery system for the treatment of macular edema. Retina 29(1), 46–51 (2009).
  • Chang-Lin JE, Attar M, Acheampong AA et al. Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest. Ophthalmol. Vis. Sci. 52(1), 80–86 (2011).
  • Chang-Lin JE, Burke JA, Peng Q et al. Pharmacokinetics of a sustained-release dexamethasone intravitreal implant in vitrectomized and nonvitrectomized eyes. Invest. Ophthalmol. Vis. Sci. 52(7), 4605–4609 (2011).
  • Kuppermann BD, Blumenkranz MS, Haller JA et al.; Dexamethasone DDS Phase II Study Group. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch. Ophthalmol. 125(3), 309–317 (2007).
  • Haller JA, Kuppermann BD, Blumenkranz MS et al.; Dexamethasone DDS Phase II Study Group. Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch. Ophthalmol. 128(3), 289–296 (2010).
  • Boyer DS, Faber D, Gupta S et al.; Ozurdex CHAMPLAIN Study Group. Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. Retina 31(5), 915–923 (2011).
  • Williams GA, Haller JA, Kuppermann BD et al.; Dexamethasone DDS Phase II Study Group. Dexamethasone posterior-segment drug delivery system in the treatment of macular edema resulting from uveitis or Irvine–Gass syndrome. Am. J. Ophthalmol. 147(6), 1048–54, 1054.e1 (2009).
  • Kuppermann BD, Haller JA, Bandello F et al. Efficacy of dexamethasone intravitreal implant for best corrected visual acuity in patients with retinal vein occlusion after 7 days. IOVS 52, 3966 (2011).
  • Yeh WS, Haller JA, Lanzetta P et al. Effect of the duration of macular edema on clinical outcomes in retinal vein occlusion treated with dexamethasone intravitreal implant. Ophthalmology 119(6), 1190–1198 (2012).
  • Kowalski JW, Rentz A, Revicki D et al. Effect of dexamethasone intravitreal implant on patient-reported visual functioning for the treatment of macular edema following retinal vein occlusion. IOVS 51, 4726 (2010).
  • Naik RK, Gelhorn H, Kowalski J et al. Efficacy of dexamethasone intravitreal implant for the treatment of uveitis based on patient-reported vision function outcome measures. IOVS 51, 5875 (2010).
  • Smiddy WE, Feuer W, Irvine WD, Flynn HW Jr, Blankenship GW. Vitrectomy for complications of proliferative diabetic retinopathy. Functional outcomes. Ophthalmology 102(11), 1688–1695 (1995).
  • Stefánsson E. Physiology of vitreous surgery. Graefes Arch. Clin. Exp. Ophthalmol. 247(2), 147–163 (2009).
  • Chin HS, Park TS, Moon YS, Oh JH. Difference in clearance of intravitreal triamcinolone acetonide between vitrectomized and nonvitrectomized eyes. Retina 25(5), 556–560 (2005).
  • Schindler RH, Chandler D, Thresher R, Machemer R. The clearance of intravitreal triamcinolone acetonide. Am. J. Ophthalmol. 93(4), 415–417 (1982).
  • Yanyali A, Aytug B, Horozoglu F, Nohutcu AF. Bevacizumab (Avastin) for diabetic macular edema in previously vitrectomized eyes. Am. J. Ophthalmol. 144(1), 124–126 (2007).
  • Loewenstein A, Kuppermann BD, Weinberger D et al. Safety and efficacy of OZURDEX™ (dexamethasone intravitreal implant) as adjunctive therapy to Lucentis® in patients with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). IOVS 51, Abstract 1255 (2010).
  • Singer M, Patel SS, Uy HS et al. Dexamethasone intravitreal implant (DEX implant) alone and as an adjunct to ranibizumab for the treatment of choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). IOVS 52, Abstract 3536 (2011).
  • Shah CP, Garg SJ, Vander JF, Brown GC, Kaiser RS, Haller JA; Post-Injection Endophthalmitis (PIE) Study Team. Outcomes and risk factors associated with endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents. Ophthalmology 118(10), 2028–2034 (2011).
  • Yau JW, Lee P, Wong TY, Best J, Jenkins A. Retinal vein occlusion: an approach to diagnosis, systemic risk factors and management. Intern. Med. J. 38(12), 904–910 (2008).
  • Rehak J, Rehak M. Branch retinal vein occlusion: pathogenesis, visual prognosis, and treatment modalities. Curr. Eye Res. 33(2), 111–131 (2008).
  • Klein R, Moss SE, Meuer SM, Klein BE. The 15-year cumulative incidence of retinal vein occlusion: the Beaver Dam Eye Study. Arch. Ophthalmol. 126(4), 513–518 (2008).
  • Mitchell P, Smith W, Chang A. Prevalence and associations of retinal vein occlusion in Australia. The Blue Mountains Eye Study. Arch. Ophthalmol. 114(10), 1243–1247 (1996).
  • Klein R, Klein BE, Moss SE, Meuer SM. The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study. Trans. Am. Ophthalmol. Soc. 98, 133–41; discussion 141 (2000).
  • The Central Vein Occlusion Study Group. Natural history and clinical management of central retinal vein occlusion. Arch. Ophthalmol. 115(4), 486–491 (1997).
  • Rogers SL, McIntosh RL, Lim L et al. Natural history of branch retinal vein occlusion: an evidence-based systematic review. Ophthalmology 117(6), 1094–1101.e5 (2010).
  • McIntosh RL, Rogers SL, Lim L et al. Natural history of central retinal vein occlusion: an evidence-based systematic review. Ophthalmology 117(6), 1113–1123.e15 (2010).
  • Gritz DC, Wong IG. Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study. Ophthalmology 111(3), 491–500; discussion 500 (2004).
  • Rothova A, Suttorp-van Schulten MS, Frits Treffers W, Kijlstra A. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br. J. Ophthalmol. 80(4), 332–336 (1996).
  • ten Doesschate J. Causes of blindness in The Netherlands. Doc. Ophthalmol. 52(3-4), 279–285 (1982).
  • Nussenblatt RB. The natural history of uveitis. Int. Ophthalmol. 14(5-6), 303–308 (1990).
  • Suttorp-Schulten MS, Rothova A. The possible impact of uveitis in blindness: a literature survey. Br. J. Ophthalmol. 80(9), 844–848 (1996).
  • Durrani OM, Tehrani NN, Marr JE, Moradi P, Stavrou P, Murray PI. Degree, duration, and causes of visual loss in uveitis. Br. J. Ophthalmol. 88(9), 1159–1162 (2004).
  • Mohamed Q, Gillies MC, Wong TY. Management of diabetic retinopathy: a systematic review. JAMA 298(8), 902–916 (2007).
  • Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophthalmology 105(10), 1801–1815 (1998).
  • Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XV. The long-term incidence of macular edema. Ophthalmology 102(1), 7–16 (1995).
  • Ferris FL III. Diabetic macular edema. In: Diabetic Retinal Renal-Syndrome. Pathogenesis and Management Update 2002. Friedman EA, L’Esperance FA Jr (Eds). Kluwer Academic Publishers, MA, USA, 47–58 (2002).
  • Diabetes Control and Complications Trial Research Group. Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial. Ophthalmology 102(4), 647–661 (1995).
  • Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema. Ophthalmology 91(12), 1464–1474 (1984).
  • Barak Y, Heroman WJ, Tezel TH. The past, present, and future of exudative age-related macular degeneration treatment. Middle East Afr. J. Ophthalmol. 19(1), 43–51 (2012).
  • Harvey PT. Common eye diseases of elderly people: identifying and treating causes of vision loss. Gerontology 49(1), 1–11 (2003).
  • National Advisory Eye Council on Vision Research. A National Plan, 1995–1998. NIH Publication 93–3186. National Institutes of Health, MD, USA (1993).
  • Friedman DS, O’Colmain BJ, Muñoz B et al.; Eye Diseases Prevalence Research Group. Prevalence of age-related macular degeneration in the United States. Arch. Ophthalmol. 122(4), 564–572 (2004).
  • Wu XS. Synthesis and properties of biodegradable lactic/glycolic acid polymers. In: Encyclopedic Handbook of Biomaterials and Bioengineering. Wise DL et al. (Eds). Marcel Dekker, NY, USA, 1015–1054 (1995).
  • de Buren N. [Studies on a new absorbable synthetic suture material (Dexon)]. Helv. Chir. Acta 37(6), 616–617 (1970).
  • The dexon polyglycolic acid suture. Med. Lett. Drugs Ther. 13(19), 79 (1971).
  • Conn J Jr, Oyasu R, Welsh M, Beal JM. Vicryl (polyglactin 910) synthetic absorbable sutures. Am. J. Surg. 128(1), 19–23 (1974).
  • Rokkanen P, Böstman O, Vainionpää S et al. Biodegradable implants in fracture fixation: early results of treatment of fractures of the ankle. Lancet 1(8443), 1422–1424 (1985).
  • Takada K. Microfabrication-derived DDS: from batch to individual production. Drug Discov. Ther. 2(3), 140–155 (2008).
  • Tamai H, Igaki K, Kyo E et al. Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans. Circulation 102(4), 399–404 (2000).

Patents

  • Taylor HF (1938). Vitamin preparations and methods of making same. US Patent 2183053.
  • Lowe CE (1954) Preparation of high molecular-weight polyhydroxyacetic ester. US Patent 2668162.

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.